News Center_News Center_Nanjing Synthgene Medical Technology Co., Ltd.

COVID-19 FluA/FluB HIV1/2 AMP HBsAg HCV

简体中文

English





简体中文

English

Your current location:

Homepage

News Center

11-16 

The event is in progress | The 53rd MEDICA opened grandly, looking back on the wonderful first day of Synthgene Medical Technology!

On November 15, 2021, the world's largest medical equipment industry exhibition, the German International Hospital and Medical Equipment Supplies Exhibition (MEDICA), grandly opened in Dusseldorf, Germany. This MEDICA exhibition attracted more than 200,000 exhibitors from more than 100 countries, and experts from various countries gathered to discuss and exchange medical cutting-edge technology. For the first time of MDICIA, Synthgene Medical Technology showed a variety of products, which attracted much attention.

10-29 

SARS-COV-2 Nucleocapsid (N) Antigen Rapid Detection Kit developed by Nanjing Synthgene Medical was successfully registered with the National Medical Products Administration of Ukraine

SARS-COV-2 Nucleocapsid (N) Antigen Rapid Detection Kit developed by Nanjing Synthgene Medical was successfully registered with the National Medical Products Administration of Ukraine.

10-24 

In the post-epidemic era of the blue ocean market--POC, Screen, Home Testing，Nanjing Synthgene Medical accelerates product line distribution!

Since the beginning of this year, the global COVID-19 epidemic has not slowed down due to the rapid vaccination of the vaccine. The global anti-epidemic situation is still severe. Different countries are experiencing the second, third or fourth peak. Statistics show that Until October 24, 2021, the cumulative number of reported cases of new COVID-19 infection worldwide has exceeded 240 million. The new COVID-19 anti-epidemic will be a protracted battle in the world!

10-19 

New Product Launch SARS-COV-2 Nucleocapsid (N) Antigen Rapid Detection Kit(Colloidal gold method)—Lollipop style

Since the beginning of this year, the global situation of the new crown epidemic remains severe, and the fight against the new crown epidemic will be a protracted global battle. In this context, the demand for new coronavirus diagnostic kits in the world continues to remain high, and the demand for antigen kits in particular will show a significant upward trend in 2021.

10-12 

SARS-COV-2 Nucleocapsid (N) Antigen Rapid Detection Kit developed by Nanjing Synthgene Medical enters the whitelist of French COVID-19 detection products

On October 12, SARS-COV-2 Nucleocapsid (N) Antigen Rapid Detection Kit(Colloidal gold method) developed by Nanjing Synthgene Medical enters the whitelist of French COVID-19 detection products

10-08 

Nanjing Synthgene Medical COVID -19 Antigen detection kit passed the laboratory test of Mahidol University in Thailand

Today, Nanjing Synthgene Medical’s SARS-COV-2 Nucleocapsid (N) Antigen Rapid Detection Kit (Colloidal gold method) Salivary was tested in the laboratory of Mahidol University in Thailand, and the test results showed 96.67% high sensitivity and 100% specificity, the quality of Nanjing Synthgene Medical products is highly recognized by the laboratory of Mahidol University in Thailand.

05-13 

Analysis on the situation of pharmaceutical foreign trade in the first quarter of 2011

In the first quarter of this year, the world economy continued to recover, the global pharmaceutical trade was heating up, the domestic pharmaceutical market developed rapidly, and the import demand for high-end pharmaceutical products increased sharply. my country's pharmaceutical trade achieved rapid growth in phases. The pharmaceutical foreign trade import and export volume reached 16.224 billion U.S. dollars, a year-on-year increase. An increase of 41.07%, of which exports were 10.119 billion U.S. dollars, an increase of 38.13% year-on-year, and imports were 6.105 billion U.S. dollars, an increase of 46.23% year-on-year. The growth rates of imports and exports were better than expected. At present, the competitive advantages of my country’s low- and mid-range pharmaceutical products are still relatively obvious, and they have been further strengthened in the process of the global pharmaceutical industry’s transfer to developing countries. In addition, my country’s pharmaceutical market has achieved remarkable results, and its exports to emerging pharmaceutical markets have developed rapidly, prompting my country’s original The export market for advantageous pharmaceutical products has further expanded. one. API products are ushering in a new growth stage, the market growth of developed countries is stable, and the emerging pharmaceutical market is developing rapidly The expansion of global generic drug market demand and industrial transfer provide opportunities and space for China's APIs to further expand into the international market. In the first quarter, my country's API exports were 5.363 billion US dollars, an increase of 31.31% year-on-year, realizing the export of APIs since the financial crisis The largest quarterly year-on-year increase. In terms of markets, exports to developed markets such as the European Union, the United States, and Japan rose steadily, with exports of US$1.414 billion, US$683 million, and US$311 million, respectively, with growth rates of 26.31%, 12.82%, and 3.23%, respectively, to the above three markets. The overall increase was 19.13%. Exports to major emerging pharmaceutical markets such as India, ASEAN, and Brazil were US$7.78, 5.03, and 158 million, up 39.15%, 45.64%, and 55.82% year-on-year, respectively. The total exports of the above three regions increased from 24.69% to 26.9%. The pharmaceutical market trade area is increasingly driving the export of raw materials and has become the regional market with the most development potential. At the same time, statistics show that the growth of the overall export volume of raw materials in the first quarter was mainly driven by export volume. The export volume increased by 39.53% and the export price fell by 5.89%. This further shows that the domestic fierce market competition has not changed, and the export phenomenon is prominent. In terms of main varieties, the export growth of traditional bulk commodities was weak. The export volume of 10 key products such as heparin sodium, vitamin C, vitamin E, and penicillin industrial salt increased by 7.23%, while the export price dropped by 16.51% and the export value dropped by 10.48%. There is a serious situation of homogeneous competition. On the other hand, the export of some APIs, such as macrolide antibiotics, hormones, chloramphenicol, and tetracycline APIs, has improved significantly, and the export prices have risen. The average prices have risen by 30.39%, 19.84%, and 31.24%, respectively. 40.05%, the export value increased by 100.35%, 23.69%, 60.72%, and 37.1% respectively. two. The export of high-end pharmaceutical products is differentiated, the export growth of preparations has declined, and the export situation of medical equipment is optimistic. In the first quarter, the export of high-end pharmaceutical products represented by western medicine preparations and diagnosis and treatment equipment diverged. Driven by the strong export of AstraZeneca Pharmaceutical Co., Ltd., the export of western medicine preparations increased by 23.71% in the first quarter. The export growth rate has declined compared with the same period last year. AstraZeneca Pharmaceutical Co., Ltd. among the foreign-funded enterprises took advantage of my country's strong raw material drug industry to transfer preparation production to China. In the first quarter, it added 73.5 million U.S. dollars in preparation exports, most of which were exported to Australia and quickly jumped to the export of western medicine preparations. First, it became the main driving force for the growth of preparations exports in the first quarter. If AstraZeneca's new export factors are not taken into account, the preparations exports in the first quarter only increased by 2%, which was a drop of nearly 1/3 compared with the same period last year. The export of preparations by state-owned and private enterprises still focuses on Asian, African and South American markets, and underdeveloped markets account

05-13 

The United States Pharmacopeia publishes new heparin quality standards

In order to ensure the quality of heparin products and prevent potential contamination, the US Pharmacopoeia Commission decided to adopt new production control methods for heparin. The revised U.S. Pharmacopoeia standard has been announced and effective on October 1.

Molecular diagnostics

News Center

Company News

Industry News

Contact Us

Address：Building B6-2, No. 9, Weidi Road, Xianlin University Town, Xianlin Subdistrict, Qixia District, Nanjing City, China
Tel: +86(025)83696681 (overseas)
Email:sales@syngenebio.com
After-sale Email ：service@syngenebio.com

E-mail

Tel

+86(025)83696681

Messages

TOP

Public Account